Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
45.3 ^USD	+1.98%		-1.93%	-24.71%

Apr. 23	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
Apr. 22	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 11, 2024 at 07:00 am EDT

Legend Biotech Corporation reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 79.46 million compared to USD 27.63 million a year ago. Net loss was USD 144.82 million compared to USD 135.88 million a year ago.

Basic loss per share from continuing operations was USD 0.8 compared to USD 0.82 a year ago. Diluted loss per share from continuing operations was USD 0.8 compared to USD 0.82 a year ago.

Latest news about Legend Biotech Corporation

Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	Apr. 23	MT
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	Apr. 22	MT
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	Apr. 22	CI
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	Apr. 17	MT
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	Apr. 17	MT
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	Apr. 08	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma	Apr. 08	MT
U.S. FDA approves expanded use of J&J's cancer cell therapy	Apr. 05	RE
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	Apr. 05	CI
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	Apr. 05	RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy	Apr. 05	RE
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	Apr. 03	MT
Legend Biotech Files Mixed-Securities Shelf Registration	Mar. 19	MT
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication	Mar. 19	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	Mar. 18	MT
Legend Biotech, Johnson & Johnson Cancer Therapy Wins FDA Advisory Panel Nod	Mar. 15	MT
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma	Mar. 15	CI
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy	Mar. 15	RE
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies	Mar. 13	RE
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	Mar. 13	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	Mar. 11	MT
Legend Biotech Corporation Announces Management Changes	Mar. 11	CI
Transcript : Legend Biotech Corporation, Q4 2023 Earnings Call, Mar 11, 2024	Mar. 11

Chart Legend Biotech Corporation

Duration

Period

More charts

Company Profile

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Legend Biotech Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.3 USD

Average target price

86.33 USD

Spread / Average Target

+90.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEGEND BIOTECH CORPORATION	-24.71%	8.24B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs